NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 213 filers reported holding NEVRO CORP in Q2 2021. The put-call ratio across all filers is 0.95 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,847,798 | +56.2% | 356,285 | +106.6% | 0.08% | +53.8% |
| Q2 2023 | $4,384,391 | -67.1% | 172,478 | -53.2% | 0.05% | -71.3% |
| Q1 2023 | $13,325,107 | +5.7% | 368,606 | +15.8% | 0.18% | +7.1% |
| Q4 2022 | $12,607,214 | -20.1% | 318,364 | -6.0% | 0.17% | -23.5% |
| Q3 2022 | $15,788,000 | -27.0% | 338,790 | -31.4% | 0.22% | -33.6% |
| Q2 2022 | $21,641,000 | +8.1% | 493,741 | +78.3% | 0.33% | +2.5% |
| Q1 2022 | $20,027,000 | +149.5% | 276,881 | +179.7% | 0.32% | +182.6% |
| Q4 2021 | $8,026,000 | -57.9% | 99,005 | -39.6% | 0.12% | -63.0% |
| Q3 2021 | $19,068,000 | +3010.6% | 163,842 | +4329.4% | 0.31% | +2727.3% |
| Q2 2021 | $613,000 | -92.5% | 3,699 | -94.7% | 0.01% | -96.7% |
| Q4 2019 | $8,138,000 | – | 69,233 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 403,424 | $46,950,000 | 6.74% |
| HealthCor Management, L.P. | 529,230 | $61,592,000 | 2.66% |
| Sante Capital Fund, LP | 18,963 | $2,207,000 | 2.04% |
| Jackson Square Partners, LLC | 2,452,497 | $285,421,000 | 1.81% |
| Altium Capital Management LP | 51,000 | $5,935,000 | 1.56% |
| Rock Springs Capital Management LP | 635,700 | $73,983,000 | 1.56% |
| PFM Health Sciences, LP | 392,786 | $45,712,000 | 1.34% |
| Redmile Group, LLC | 542,932 | $63,186,000 | 1.10% |
| Connacht Asset Management LP | 13,555 | $1,578,000 | 1.02% |
| Integral Health Asset Management, LLC | 30,000 | $3,491,000 | 1.00% |